INT42485

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 1981
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 9
Total Number 12
Disease Relevance 3.42
Pain Relevance 3.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Pah)
Anatomy Link Frequency
lymphocytes 2
T lymphocyte 2
heart 1
Pah (Mus musculus)
Pain Link Frequency Relevance Heat
Enkephalin 8 100.00 Very High Very High Very High
Opioid 8 98.24 Very High Very High Very High
Potency 8 97.34 Very High Very High Very High
mu opioid receptor 5 95.12 Very High Very High Very High
Morphine 5 94.76 High High
Inflammatory mediators 6 89.64 High High
opioid receptor 4 89.04 High High
opiate 1 86.12 High High
Calcium channel 6 83.28 Quite High
tail-flick 6 82.08 Quite High
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 198 100.00 Very High Very High Very High
Frailty 4 99.60 Very High Very High Very High
Disease 57 98.88 Very High Very High Very High
Toxicity 14 94.56 High High
Apoptosis 8 92.56 High High
Hypoxia 12 92.32 High High
Hyperplasia 3 92.00 High High
INFLAMMATION 36 89.24 High High
Cv General 4 Under Development 66 88.64 High High
Stress 22 88.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Given the costs associated with PAH therapy and potential for drug interactions and side effects, caution is advised when attempting combination therapy.
PAH Binding (associated) of associated with pulmonary hypertension
1) Confidence 0.35 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 0.64 Pain Relevance 0.03
Antiproliferative effects of NO have been well described.10,11 The importance of NO in PAH is magnified because PAH is intrinsically associated with reduced endogenous NO production.
PAH Binding (associated) of associated with pulmonary hypertension
2) Confidence 0.34 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 0.95 Pain Relevance 0
These key pathways currently serve as targets for disease-specific treatment modalities that have revolutionized PAH management, by improving functional capacity, hemodynamics, and patient well being.5 In PAH, the ideal pharmacologic agents should facilitate vasorelaxation and restoration of the balance between apoptosis and cellular proliferation, ultimately preserving RV function and delaying the onset of right heart failure.6
PAH Binding (management) of in heart associated with pulmonary hypertension, cv general 4 under development, apoptosis, disease and hyperplasia
3) Confidence 0.30 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 1.27 Pain Relevance 0.09
There was no significant association between total PAH and any T lymphocyte fractions for months three through six.
PAH Neg (no) Binding (association) of in T lymphocyte
4) Confidence 0.20 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
In fetal mice, hypocellularity and atrophy of the thymus were associated with PAH and BaP exposure respectively [36,37], making our findings all the more relevant given that the thymus plays a critical role in differentiation, maturation and selection of T lymphocytes.
PAH Binding (associated) of in T lymphocytes associated with frailty
5) Confidence 0.15 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0.23 Pain Relevance 0.03
To identify potential critical time windows during gestation, we fit multivariable linear regression models to associate lymphocyte percentages with monthly average PAH and PM2.5 exposures, separately.
PAH Binding (associate) of in lymphocyte
6) Confidence 0.13 Published 2010 Journal Environ Health Section Body Doc Link PMC2927516 Disease Relevance 0.07 Pain Relevance 0
Multivariable linear regression models were fitted to estimate associations between monthly PAH or PM2.5 and cord blood lymphocytes, adjusting for year of birth and district of residence and, in further models, gestational season and number of prior live births.


PAH Binding (associations) of in lymphocytes
7) Confidence 0.13 Published 2010 Journal Environ Health Section Abstract Doc Link PMC2927516 Disease Relevance 0 Pain Relevance 0
There is an excellent correlation between the PAH content of UFP and their ability to engage in redox cycling reactions in-vitro.
PAH Binding (engage) of
8) Confidence 0.09 Published 2009 Journal Part Fibre Toxicol Section Body Doc Link PMC2761850 Disease Relevance 0.17 Pain Relevance 0
Incubation of membranes with N-CBM-TAMO resulted in wash-resistant inhibition of the binding of the mu-selective peptide [3H][D-Ala2,(Me)Phe4, Gly(ol)5]-enkephalin, the kappa-selective opioid [3H]U69,593 ((trans)-3, 4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzenacetamide+ ++ methanesulfonate hydrate)) and, to a lesser extent, the delta-selective peptide [D-Pen2, p-Cl-phenylalanine4, D-Pen5]enkephalin.
Phe4 Binding (binding) of associated with enkephalin and opioid
9) Confidence 0.01 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8930155 Disease Relevance 0 Pain Relevance 0.75
These subsites are suggested to be identical with those which recognize the aromatic rings of the Tyr1 and Phe4 of the enkephalins and endorphins.
Phe4 Binding (recognize) of associated with enkephalin
10) Confidence 0.01 Published 1981 Journal J. Med. Chem. Section Abstract Doc Link 6268787 Disease Relevance 0 Pain Relevance 0.69
Scatchard analysis of saturation binding data showed that N-CBM-TAMO decreased the Bmax value without affecting the Kd value for [3H][D-Ala2,(Me)Phe4, Gly(ol)5]enkephalin binding, whereas, N-CBM-TAMO increased the Kd value without altering the Bmax value for [3H]U69,593, which suggests that N-CBM-TAMO interacted covalently with the mu but not the kappa receptor.
Phe4 Binding (binding) of associated with enkephalin
11) Confidence 0.01 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8930155 Disease Relevance 0 Pain Relevance 1.02
The observation that Phe(pNO2) substitution in position 3 of morphiceptin and dermorphin also produces a drastic potency drop indicates that the Phe3 side-chain of the latter peptides at the mu- and delta-receptor may bind to a site different from that interacting with the Phe4 side-chain of enkephalins.
Phe4 Binding (interacting) of associated with enkephalin and potency
12) Confidence 0.00 Published 1983 Journal Life Sci. Section Abstract Doc Link 6319885 Disease Relevance 0.08 Pain Relevance 0.43

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox